Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic randomized comparison of SGLT-2 inhibitors in elderly patients with type 2 diabetes
2021-001167-24Phase 4Active
- Sponsor
- Società Italiana di Diabetologia
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin arm, Canagliflozin arm and Empagliflozin arm (3 arms). Primary endpoint: Glucose control without level-3 hypoglycemia. Started Aug 2021; status: active.
02
Drugs
dapagliflozincanagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-001167-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001167-24.